Lumida
/TSHA
⌘K
Taysha Gene Therapies Inc

Taysha Gene Therapies Inc

TSHA
$5.96USD↓-0.17%-0.01 today

MARKET CAP

1.9B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $6

52W RANGE

$2
$7

AI Summary

Stalk
Sell NowMedium

TSHA is in a Stage 4 decline with medium-term bearish tradability supported by a Lower Highs & Lower Lows pattern and recent price rejection at the 9/20/50 EMA cluster. Short-term execution favors selling now amid persistent downward momentum. Long-term uptrend remains intact above the 200 DMA but is secondary to the current decline.

  • ↑100% patient response in early TASHA-102 trials achieving key milestones.
  • ↑Breakthrough therapy designation from FDA streamlines regulatory approval process.
  • ↓Net loss of $109M in 2025 widens operating deficits.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology firm focused on advancing gene therapies for rare neurodevelopmental disorders, particularly Rett syndrome. With a primary focus on its lead candidate, TASHA-102, Taysha is well-positioned within the gene therapy market, aiming to address significant unmet medical needs associated with this condition. The company's innovative approach aims to restore MECP2 protein expression, thus targeting the root causes of Rett syndrome.

Bull says

  • ↑100% patient response in early TASHA-102 trials achieving key milestones.
  • ↑Breakthrough therapy designation from FDA streamlines regulatory approval process.
  • ↑Cash runway of $319.8M supports operations and trials into 2028.
  • ↑Addressable market of ~15k–20k Rett syndrome patients underscores growth potential.
  • ↑Analysts raised price target to $15, indicating upside potential.
  • ↑Attractive dividend yield, strong liquidity, high institutional ownership, and positive momentum.

Bear says

  • ↓Net loss of $109M in 2025 widens operating deficits.
  • ↓R&D spending at $86.4M accelerates cash burn.
  • ↓FDA approval timeline remains uncertain, risking commercialization delays.
  • ↓Emerging gene therapy competitors could erode market share.
  • ↓High stock volatility increases investor risk.
  • ↓Negative earnings yield, weak profitability, and poor growth raise caution.

Investment themes with TSHA

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-03-2026neutral

Transcript signals

Bull points

  • In 2025, we finalized alignment with the FDA on our Reveal Pivotal Trial Protocol and Statistical Analysis Plan in support of our Plan BLA submission.
  • Multiple patients have now been dosed in the trial, with enrollment advancing across multiple sites.
  • Importantly, both high- and low-dose TASIA-102 continues to be generally well-tolerated, with no treatment-related serious adverse events or dose-limiting toxicities observed in the patients treated in both the Reveal Phase 1-2 and Reveal Pivotal Trial as of the March 2026 data cutoff.

Bear points

  • Research and development expenses were $86.4 million for the year ended December 31, 2025, compared to $66 million for the year ended December 31, 2024. The $20.4 million increase was primarily driven by higher compensation expenses due to increased research and development headcount.
  • General and administrative expenses were $33.9 million for the year ended December 31st, 2025 compared to $29 million for the year ended December 31st, 2024. The increase of $4.9 million was primarily due to higher compensation expenses and higher legal and professional fees as well as debt issuance costs incurred in connection with the 2025 Trinity Term Loan that are recorded in general and administrative expense under the fair value option.
  • Net loss for the year ended December 31st, 2025 was $109 million or 34 cents per share compared to a net loss of $89.3 million or 36 cents per share for the year ended December 31st, 2024.
Read full transcript analysis ›